Endometrial cancer survival after breast cancer in relation to tamoxifen treatment: Pooled results from three countries

Table 3 Follow-up, vital status and cause of death for patients with endometrial cancer after breast cancer, by study

	Study						Combined
	NL		UK		US
Number of subjects	765		786		324		1875
Total follow-up time (person-years)	2,676.6		5,552.2		2,731.5		10,960.3
Maximum follow-up (years)	16.6		20.3		25.5		25.5
Median length of follow-up (years)	2.6		5.2		8.1		4.0
Vital status at end of follow-up (n, %)
Alive	470	61.4%	202	26%	99	31%	771	41.1%
Deceased	295	38.6%	584	74%	225	69%	1,104	58.9%
Cause of death (n, %)
Breast cancer	92	31%	198	34%	63	28%	353	32.0%
Endometrial cancer	85	29%	151	26%	41	18%	277	25.1%
Breast or cancer^a	28	9%	9	2%	0	0%	37	3.4%
All other causes^{b, c}	90	31%	226	39%	121	54%	437	39.6%
All causes	295	100%	584	100%	225	100%	1,104	100.0%
Survival (95% CI): all cause mortality
1-year survival	87% (84%, 89%)		81% (78%, 83%)		87% (83%, 90%)		84.4% (82.7%, 86.0%)
5-year survival	57% (53%, 61%)		51% (48%, 55%)		61% (56%, 66%)		55.5% (53.1%, 57.9%)
Survival (95% CI): endometrial cancer mortality^d
1-year survival	93% (91%, 95%)		89% (87%, 91%)		94% (91%, 96%)		91.8% (90.5%, 93.0%)
5-year survival	86% (83%, 88%)		81% (78%, 84%)		87% (82%, 90%)		83.8% (81.9%, 85.6%)

^aNot possible to differentiate between breast and endometrial cancer as cause of death; ^b15 (2.6%) patients in UK and 4 (1.8%) in the USA study had cancer as cause of death, but primary site unknown; ^c4 (1.4%) patients in NL and 2 (0.3%) in UK study had an unknown cause of death; ^ddeaths due to causes other than endometrial cancer are censored on date of death. CI, confidence interval; n, number.

ISSN: 1465-542X